A phase III clinical trial of exercise modalities on treatment side-effects in men receiving therapy for prostate cancer

BMC Cancer

Volumn 9, Issue , 2009, Pages

  Newton, Robert U ^a   Taaffe, Dennis R ^b   Spry, Nigel ^c,d   Gardiner, Robert A ^b   Levin, Gregory ^a   Wall, Bradley ^a   Joseph, David ^c,d   Chambers, Suzanne K ^e   Galvão, Daniel A ^a  

^a EDITH COWAN UNIVERSITY   (Australia)

^b UNIVERSITY OF QUEENSLAND   (Australia)

^c SIR CHARLES GAIRDNER HOSPITAL   (Australia)

^d UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^e GRIFFITH UNIVERSITY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIANDROGEN; ANDROGEN; ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS;

ANDROGEN DEPRIVATION THERAPY; ARTICLE; BODY FAT DISTRIBUTION; BONE DENSITY; CANCER HORMONE THERAPY; CANCER SURVIVAL; CARDIOVASCULAR DISEASE; CARDIOVASCULAR FUNCTION; CLINICAL EFFECTIVENESS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIABETES MELLITUS; FALL RISK; HUMAN; INSULIN METABOLISM; KINESIOTHERAPY; LEAN BODY WEIGHT; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MUSCULOSKELETAL DISEASE; OXYGEN CONSUMPTION; PHASE 3 CLINICAL TRIAL; PHYSICAL CAPACITY; PROSTATE CANCER; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; RISK REDUCTION; SURVIVAL RATE; TREADMILL EXERCISE; TREATMENT DURATION; TREATMENT RESPONSE; BLOOD PRESSURE; BODY COMPOSITION; EXERCISE; METABOLISM; METHODOLOGY; PROSTATE TUMOR; RISK FACTOR;

ANDROGEN ANTAGONISTS; ANDROGENS; ANTINEOPLASTIC AGENTS, HORMONAL; BLOOD PRESSURE; BODY COMPOSITION; CARDIOVASCULAR DISEASES; DIABETES MELLITUS; EXERCISE; HUMANS; MALE; PROSTATIC NEOPLASMS; RESEARCH DESIGN; RISK FACTORS;

EID: 68049130065     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-9-210     Document Type: Article

References (40)

1. Parkin DM Bray F Ferlay J Pisani P Global cancer statistics, 2002 CA Cancer J Clin 2005, 55(2):74-108. 10.3322/canjclin.55.2.74 15761078
2. Yancik R Cancer burden in the aged: An epidemiologic and demographic overview Cancer 1997, 80(7):1273-1283. 10.1002/ (SICI)1097-0142(19971001)80:7<1273::AID-CNCR13>3.0.CO;2-4 9317180
3. Yancik R Ganz PA Varricchio CG Conley B Perspectives on comorbidity and cancer in older patients: Approaches to expand the knowledge base J Clin Oncol 2001, 19(4):1147-1151. 11181680
4. McCredie M Cox B Prostate-specific antigen testing for prostate cancer: the case for informed consent Med J Aust 1998, 169(1):9-10. 9695692
5. Moul JW Prostate specific antigen only progression of prostate cancer J Urol 2000, 163(6):1632-1642. 10.1016/S0022-5347(05)67511-8 10799151
6. Rashid MH Chaudhary UB Intermittent androgen deprivation therapy for prostate cancer Oncologist 2004, 9(3):295-301. 10.1634/ theoncologist.9-3-295 15169984
7. Chodak GW Comparing treatments for localized prostate cancer-persisting uncertainty JAMA 1998, 280(11):1008-1010. 10.1001/jama.280.11.1008 9749485
8. Ransohoff DF McNaughton Collins M Fowler FJ Why is prostate cancer screening so common when the evidence is so uncertain? A system without negative feedback Am J Med 2002, 113(8):663-667. 10.1016/ S0002-9343(02)01235-4 12505117
9. Shahinian VB Kuo YF Freeman JL Goodwin JS Risk of fracture after androgen deprivation for prostate cancer N Engl J Med 2005, 352(2):154-164. 1920183 15647578 10.1056/NEJMoa041943
10. Smith MR Lee WC Brandman J Wang Q Botteman M Pashos CL Gonadotropin-releasing hormone agonists and fracture risk: A claims-based cohort study of men with nonmetastatic prostate cancer J Clin Oncol 2005, 23(31):7897-7903. 10.1200/JCO.2004.00.6908 16258089
11. Smith MR Finkelstein JS McGovern FJ Zietman AL Fallon MA Schoenfeld DA Kantoff PW Changes in body composition during androgen deprivation therapy for prostate cancer J Clin Endocrinol Metab 2002, 87(2):599-603. 10.1210/jc.87.2.599 11836291
12. Basaria S Lieb J 2nd Tang AM DeWeese T Carducci M Eisenberger M Dobs AS Long-term effects of androgen deprivation therapy in prostate cancer patients Clin Endocrinol (Oxf) 2002, 56(6):779-786. 10.1046/ j.1365-2265.2002.01551.x 12072048
13. Spry NA Kristjanson L Hooton B Hayden L Neerhut G Gurney H Corica T Korbel E Weinstein S McCaul K Adverse effects to quality of life arising from treatment can recover with intermittent androgen suppression in men with prostate cancer Eur J Cancer 2006, 42(8):1083-1092. 10.1016/ j.ejca.2006.01.029 16632343
14. Keating NL O'Malley AJ Smith MR Diabetes and cardiovascular disease during androgen deprivation therapy for prostate cancer J Clin Oncol 2006, 24(27):4448-4456. 10.1200/JCO.2006.06.2497 16983113
15. Green HJ Pakenham KI Headley BC Yaxley J Nicol DL Mactaggart PN Swanson CE Watson RB Gardiner RA Quality of life compared during pharmacological treatments and clinical monitoring for non-localized prostate cancer: A randomized controlled trial BJU Int 2004, 93(7):975-979. 10.1111/ j.1464-410X.2004.04763.x 15142146
16. Eton DT Lepore SJ Prostate cancer and health-related quality of life: A review of the literature Psychooncology 2002, 11(4):307-326. 2593110 12203744 10.1002/pon.572
17. Steginga SK Pinnock C Gardner M Gardiner RA Dunn J Evaluating peer support for prostate cancer: The Prostate Cancer Peer Support Inventory BJU Int 2005, 95(1):46-50. 10.1111/j.1464-410X.2005.05247.x 15663527
18. Wei M Kampert JB Barlow CE Nichaman MZ Gibbons LW Paffenbarger RS Jr Blair SN Relationship between low cardiorespiratory fitness and mortality in normal-weight, overweight, and obese men JAMA 1999, 282(16):1547-1553. 10.1001/jama.282.16.1547 10546694
19. Paffenbarger RS Jr Hyde RT Wing AL Lee IM Jung DL Kampert JB The association of changes in physical-activity level and other lifestyle characteristics with mortality among men N Engl J Med 1993, 328(8):538-545. 10.1056/NEJM199302253280804 8426621
20. Galvão DA Nosaka K Taaffe DR Spry N Kristjanson LJ McGuigan MR Suzuki K Yamaya K Newton RU Resistance training and reduction of treatment side effects in prostate cancer patients Med Sci Sports Exerc 2006, 38(12):2045-2052. 10.1249/01.mss.0000233803.48691.8b 17146309
21. Galvão DA Nosaka K Taaffe DR Peake J Spry N Suzuki K Yamaya K McGuigan MR Kristjanson LJ Newton RU Endocrine and immune responses to resistance training in prostate cancer patients Prostate Cancer Prostatic Dis 2008, 11(2):160-165. 10.1038/sj.pcan.4500991 17637762
22. Galvão DA Newton RU Taaffe DR Spry N Can exercise ameliorate the increased risk of cardiovascular disease and diabetes associated with ADT? Nat Clin Pract Urol 2008, 5(6):306-307. 10.1038/ncpgasthep1141 18431358
23. Galvão DA Taaffe DR Spry N Newton RU Exercise can prevent and even reverse adverse effects of androgen suppression treatment in men with prostate cancer Prostate Cancer Prostatic Dis 2007, 10(4):340-346. 10.1038/sj.pcan.4500975 17486110
24. Segal RJ Reid RD Courneya KS Malone SC Parliament MB Scott CG Venner PM Quinney HA Jones LW D'Angelo ME et al Resistance exercise in men receiving androgen deprivation therapy for prostate cancer J Clin Oncol 2003, 21(9):1653-1659. 10.1200/JCO.2003.09.534 12721238
25. Windsor PM Nicol KF Potter J A randomized, controlled trial of aerobic exercise for treatment-related fatigue in men receiving radical external beam radiotherapy for localized prostate carcinoma Cancer 2004, 101(3):550-557. 10.1002/cncr.20378 15274068
26. Taaffe DR Duret C Wheeler S Marcus R Once-weekly resistance exercise improves muscle strength and neuromuscular performance in older adults J Am Geriatr Soc 1999, 47(10):1208-1214. 10522954
27. Galvão DA Taaffe DR Resistance exercise dosage in older adults: single- versus multiset effects on physical performance and body composition J Am Geriatr Soc 2005, 53(12):2090-2097. 10.1111/ j.1532-5415.2005.00494.x 16398892
28. Galvão DA Spry NA Taaffe DR Newton RU Stanley J Shannon T Rowling C Prince R Changes in muscle, fat and bone mass after 36 weeks of maximal androgen blockade for prostate cancer BJU Int 2008, 102(1):44-47. 10.1111/j.1464-410X.2008.07539.x 18336606
29. Aaronson NK Ahmedzai S Bergman B Bullinger M Cull A Duez NJ Filiberti A Flechtner H Fleishman SB de Haes JC et al The European Organization for Research and Treatment of Cancer QLQ-C30: A quality-of-life instrument for use in international clinical trials in oncology J Natl Cancer Inst 1993, 85(5):365-376. 10.1093/jnci/85.5.365 8433390
30. Chambers SK Lynch BM Aitken J Baade P Relationship Over Time Between Psychological Distress and Physical Activity in Colorectal Cancer Survivors J Clin Oncol 2009, 27(10):1600-6. 10.1200/JCO.2008.18.5157 19255326
31. Newton RU Hakkinen K Hakkinen A McCormick M Volek J Kraemer WJ Mixed-methods resistance training increases power and strength of young and older men Med Sci Sports Exerc 2002, 34(8):1367-1375. 10.1097/ 00005768-200208000-00020 12165694
32. Taaffe DR Pruitt L Pyka G Guido D Marcus R Comparative effects of high- and low-intensity resistance training on thigh muscle strength, fiber area, and tissue composition in elderly women Clin Physiol 1996, 16(4):381-392. 10.1111/j.1475-097X.1996.tb00727.x 8842574
33. Taaffe DR Galvão DA Sharman JE Coombes JS Reduced central blood pressure in older adults following progressive resistance training J Hum Hypertens 2007, 21(1):96-98. 10.1038/sj.jhh.1002115 17096007
34. Cheng S Sipila S Taaffe DR Puolakka J Suominen H Change in bone mass distribution induced by hormone replacement therapy and high-impact physical exercise in post-menopausal women Bone 2002, 31(1):126-135. 10.1016/S8756-3282(02)00794-9 12110425
35. Holmes-Walker DJ Woo H Gurney H Do VT Chipps DR Maintaining bone health in patients with prostate cancer Med J Aust 2006, 184(4):176-179. 16489902
36. Greenspan SL Coates P Sereika SM Nelson JB Trump DL Resnick NM Bone loss after initiation of androgen deprivation therapy in patients with prostate cancer J Clin Endocrinol Metab 2005, 90(12):6410-6417. 10.1210/ jc.2005-0183 16189261
37. Kiratli BJ Srinivas S Perkash I Terris MK Progressive decrease in bone density over 10 years of androgen deprivation therapy in patients with prostate cancer Urology 2001, 57(1):127-132. 10.1016/ S0090-4295(00)00895-5 11164157
38. Ferrara CM Goldberg AP Ortmeyer HK Ryan AS Effects of aerobic and resistive exercise training on glucose disposal and skeletal muscle metabolism in older men J Gerontol A Biol Sci Med Sci 2006, 61(5):480-487. 16720745
39. Pratley RE Hagberg JM Dengel DR Rogus EM Muller DC Goldberg AP Aerobic exercise training-induced reductions in abdominal fat and glucose-stimulated insulin responses in middle-aged and older men J Am Geriatr Soc 2000, 48(9):1055-1061. 10983904
40. Eckert AW Maurer P Meyer L Kriwalsky MS Rohrberg R Schneider D Bilkenroth U Schubert J Bisphosphonate-related jaw necrosis-severe complication in maxillofacial surgery Cancer Treat Rev 2007, 33(1):58-63. 10.1016/j.ctrv.2006.09.003 17084033